723 related articles for article (PubMed ID: 23442094)
1. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
[TBL] [Abstract][Full Text] [Related]
2. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
Rapti K; Grimm D
Front Immunol; 2021; 12():753467. PubMed ID: 34777364
[TBL] [Abstract][Full Text] [Related]
3. Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions.
Weber T
Front Immunol; 2021; 12():658399. PubMed ID: 33815421
[TBL] [Abstract][Full Text] [Related]
4. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
[TBL] [Abstract][Full Text] [Related]
5. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
6. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
[TBL] [Abstract][Full Text] [Related]
7. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.
Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B
AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.
Tse LV; Klinc KA; Madigan VJ; Castellanos Rivera RM; Wells LF; Havlik LP; Smith JK; Agbandje-McKenna M; Asokan A
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4812-E4821. PubMed ID: 28559317
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
[TBL] [Abstract][Full Text] [Related]
11. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
Hamilton BA; Wright JF
Front Immunol; 2021; 12():675897. PubMed ID: 34084173
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
Mingozzi F; Chen Y; Edmonson SC; Zhou S; Thurlings RM; Tak PP; High KA; Vervoordeldonk MJ
Gene Ther; 2013 Apr; 20(4):417-24. PubMed ID: 22786533
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
[TBL] [Abstract][Full Text] [Related]
16. Genetic Engineering of AAV Capsid Gene for Gene Therapy Application.
Liu Y; Zhang X; Yang L
Curr Gene Ther; 2020; 20(5):321-332. PubMed ID: 32998676
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
Desrosiers M; Dalkara D
Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
[TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.
Chicoine LG; Montgomery CL; Bremer WG; Shontz KM; Griffin DA; Heller KN; Lewis S; Malik V; Grose WE; Shilling CJ; Campbell KJ; Preston TJ; Coley BD; Martin PT; Walker CM; Clark KR; Sahenk Z; Mendell JR; Rodino-Klapac LR
Mol Ther; 2014 Feb; 22(2):338-347. PubMed ID: 24196577
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
Masat E; Pavani G; Mingozzi F
Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
[TBL] [Abstract][Full Text] [Related]
20. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
